JP2011504362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504362A5 JP2011504362A5 JP2010534367A JP2010534367A JP2011504362A5 JP 2011504362 A5 JP2011504362 A5 JP 2011504362A5 JP 2010534367 A JP2010534367 A JP 2010534367A JP 2010534367 A JP2010534367 A JP 2010534367A JP 2011504362 A5 JP2011504362 A5 JP 2011504362A5
- Authority
- JP
- Japan
- Prior art keywords
- oligomer
- seq
- nucleotide sequence
- lna
- oligomer according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 17
- 239000002773 nucleotide Substances 0.000 claims 12
- 108010080146 androgen receptors Proteins 0.000 claims 6
- 239000000178 monomer Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 102000001307 androgen receptors Human genes 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 108020004999 messenger RNA Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99012507P | 2007-11-26 | 2007-11-26 | |
| US60/990,125 | 2007-11-26 | ||
| PCT/DK2008/000417 WO2009068033A2 (en) | 2007-11-26 | 2008-11-26 | Lna antagonists targeting the androgen receptor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208689A Division JP2016105703A (ja) | 2007-11-26 | 2015-10-23 | アンドロゲン受容体を標的化するｌｎａアンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011504362A JP2011504362A (ja) | 2011-02-10 |
| JP2011504362A5 true JP2011504362A5 (https=) | 2011-12-08 |
| JP5872162B2 JP5872162B2 (ja) | 2016-03-01 |
Family
ID=40379703
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534367A Expired - Fee Related JP5872162B2 (ja) | 2007-11-26 | 2008-11-26 | アンドロゲン受容体を標的化するｌｎａアンタゴニスト |
| JP2015208689A Pending JP2016105703A (ja) | 2007-11-26 | 2015-10-23 | アンドロゲン受容体を標的化するｌｎａアンタゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015208689A Pending JP2016105703A (ja) | 2007-11-26 | 2015-10-23 | アンドロゲン受容体を標的化するｌｎａアンタゴニスト |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7737125B2 (https=) |
| EP (1) | EP2225377B1 (https=) |
| JP (2) | JP5872162B2 (https=) |
| KR (1) | KR20100110298A (https=) |
| CN (1) | CN101932709B (https=) |
| AU (1) | AU2008329327B2 (https=) |
| BR (1) | BRPI0820508A2 (https=) |
| CA (1) | CA2705714A1 (https=) |
| DK (1) | DK2225377T3 (https=) |
| EA (1) | EA020026B1 (https=) |
| ES (1) | ES2456990T3 (https=) |
| IL (2) | IL205944A (https=) |
| MX (1) | MX2010005703A (https=) |
| NZ (1) | NZ585327A (https=) |
| TW (1) | TW200930382A (https=) |
| UA (1) | UA100253C2 (https=) |
| WO (1) | WO2009068033A2 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| EP2213737B1 (en) | 2002-02-01 | 2012-11-07 | Life Technologies Corporation | Double-stranded oligonucleotides |
| DK2548962T3 (en) | 2007-09-19 | 2016-04-11 | Applied Biosystems Llc | Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof |
| US8450290B2 (en) * | 2007-11-26 | 2013-05-28 | Enzon Pharmaceuticals, Inc. | Methods for treating androgen receptor dependent disorders including cancers |
| EP3210611B1 (en) | 2010-03-12 | 2019-08-21 | The Brigham and Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
| WO2012024255A2 (en) * | 2010-08-16 | 2012-02-23 | Duke University | Camkk-beta as a target for treating cancer |
| US20140031250A1 (en) | 2010-10-07 | 2014-01-30 | David Tsai Ting | Biomarkers of Cancer |
| WO2012065051A1 (en) | 2010-11-12 | 2012-05-18 | Enzon Pharmaceuticals, Inc. | Compositions and methods for treating androgen receptor dependent disorders including cancers |
| EP3260540A1 (en) | 2010-11-12 | 2017-12-27 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| EP2663323B1 (en) | 2011-01-14 | 2017-08-16 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
| SI2717883T1 (sl) | 2011-05-02 | 2017-06-30 | Stichting Vumc | Zaščita pred motnjo endotelijske pregrade z inhibicijo tirozin kinaze ABL-sorodnega gena (ARG) |
| CA2851280C (en) | 2011-10-11 | 2021-05-18 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
| NZ740700A (en) * | 2012-07-27 | 2019-07-26 | Aragon Pharmaceuticals Inc | Methods and compositions for determining resistance to androgen receptor therapy |
| CN104955950B (zh) | 2012-09-26 | 2019-04-26 | 米尔克斯治疗学公司 | 具有改善的脱靶特征谱的寡核苷酸 |
| US9523094B2 (en) | 2012-10-11 | 2016-12-20 | Ionis Pharmaceuticals, Inc. | Methods of treating kennedy's disease |
| US9175291B2 (en) * | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| US10077443B2 (en) | 2012-11-15 | 2018-09-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
| CN104955952A (zh) * | 2013-01-30 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | Lna寡核苷酸碳水化合物缀合物 |
| EP2774997A1 (en) * | 2013-03-05 | 2014-09-10 | Bayer Pharma Aktiengesellschaft | Detection of Androgen Receptor (AR) mutations in circulating tumor DNA from plasma samples of castration-resistant prostate cancer patients using locked nucleic acid-clamp PCR |
| WO2014171826A1 (en) | 2013-04-17 | 2014-10-23 | Stichting Vu-Vumc | Treatment of cognitive impairment in depressive disorders |
| CN105164261B (zh) | 2013-05-01 | 2022-03-18 | 莱古路斯治疗法股份有限公司 | 用于增强的细胞摄取的化合物和方法 |
| SG11201508925WA (en) | 2013-05-01 | 2015-11-27 | Regulus Therapeutics Inc | Microrna compounds and methods for modulating mir-122 |
| AU2014306416B2 (en) * | 2013-08-16 | 2021-02-25 | Translate Bio Ma, Inc. | Compositions and methods for modulating RNA |
| US10301624B2 (en) | 2014-06-25 | 2019-05-28 | The General Hospital Corporation | Targeting human satellite II (HSATII) |
| ES2985036T3 (es) | 2014-08-29 | 2024-11-04 | Childrens Medical Ct Corp | Métodos y composiciones para el tratamiento del cáncer |
| WO2016114655A1 (en) | 2015-01-12 | 2016-07-21 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
| WO2016130943A1 (en) | 2015-02-13 | 2016-08-18 | Rana Therapeutics, Inc. | Hybrid oligonucleotides and uses thereof |
| US10961532B2 (en) | 2015-04-07 | 2021-03-30 | The General Hospital Corporation | Methods for reactivating genes on the inactive X chromosome |
| CA2990852A1 (en) | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
| WO2017065602A1 (en) | 2015-10-13 | 2017-04-20 | Ry Pharma B.V. | Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation |
| WO2017066796A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
| WO2017066712A2 (en) | 2015-10-16 | 2017-04-20 | The Children's Medical Center Corporation | Modulators of telomere disease |
| EP3368089B1 (en) | 2015-10-26 | 2025-11-05 | Translate Bio Ma, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
| AU2016355178B9 (en) | 2015-11-19 | 2019-05-30 | Massachusetts Institute Of Technology | Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity |
| US11234996B2 (en) | 2016-02-25 | 2022-02-01 | The Brigham And Women's Hospital, Inc. | Treatment methods for fibrosis targeting SMOC2 |
| JP2019509053A (ja) | 2016-03-24 | 2019-04-04 | ウニフェルシタイト・ライデン | 植物にトランスフェクトする方法及びランダム組込み事象の低減方法 |
| EP3444345B1 (en) * | 2016-04-14 | 2024-07-10 | e-NA Biotec Inc. | microRNA-143 DERIVATIVE |
| EP3497114B1 (en) * | 2016-08-08 | 2024-10-16 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
| CA3037046A1 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
| WO2018093919A1 (en) * | 2016-11-15 | 2018-05-24 | City Of Hope | Methods for intracellular delivery and enhanced gene targeting |
| WO2018111099A1 (en) | 2016-12-12 | 2018-06-21 | Stichting Vumc | Biomarkers and treatments for cerebral amyloid angiopathy (caa) |
| EP3609521A4 (en) | 2017-04-14 | 2021-06-16 | University of Massachusetts | TARGETING OF CELL TROPISM RECEPTORS TO INHIBIT INFECTION BY THE CYTOMEGALOVIRUS |
| WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
| US11821003B2 (en) | 2017-08-14 | 2023-11-21 | Sanford Burnham Prebys Medical Discovery Institute | Cardiogenic mesoderm formation regulators |
| WO2019089216A1 (en) | 2017-11-01 | 2019-05-09 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
| EP3502259A1 (en) | 2017-12-19 | 2019-06-26 | Universiteit Leiden | A combinational strategy for reducing random integration events when transfecting plants |
| EP3790972A1 (en) | 2018-05-08 | 2021-03-17 | Regulus Therapeutics Inc. | Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect |
| US12582702B2 (en) | 2018-05-11 | 2026-03-24 | University Of Massachusetts | Methods for improving leptin sensitivity for the treatment of obesity and diabetes |
| EP3843845B1 (en) | 2018-08-29 | 2026-03-11 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
| WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
| GB201817990D0 (en) * | 2018-11-02 | 2018-12-19 | Univ Of Essex Enterprise Limited | Enzymatic nucleic acid molecules |
| KR102473989B1 (ko) * | 2018-11-28 | 2022-12-07 | (주)바이오니아 | 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물 |
| WO2020148400A1 (en) * | 2019-01-16 | 2020-07-23 | Stichting Katholieke Universiteit | Antisense oligonucleotides for use in the treatment of crpc |
| WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
| KR20230170022A (ko) * | 2021-04-12 | 2023-12-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 척수 및 연수 근위축증(sbma) 치료에 유용한 조성물 |
| CN119144604B (zh) * | 2024-09-14 | 2025-10-24 | 中山大学 | 一种治疗雄激素性脱发的siRNA、纳米制剂及其制备方法 |
| CN121065176A (zh) * | 2025-04-14 | 2025-12-05 | 羿美诚健(上海)生物医药有限公司 | 靶向雄激素受体的小核酸及其药物组合物和用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962029A (en) * | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| US4914210A (en) * | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US6733776B1 (en) * | 1992-04-02 | 2004-05-11 | Anticancer, Inc. | Method for promoting hair growth |
| ATE209887T1 (de) | 1993-04-02 | 2001-12-15 | Anticancer Inc | Verfahren zur verabreichung von förderlichen zusammensetzungen auf die haarfollikel |
| EP0851919A1 (en) | 1995-09-20 | 1998-07-08 | University of Massachusetts Worcester | Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate |
| US6489163B1 (en) * | 1996-05-08 | 2002-12-03 | Board Of Regents, The University Of Texas System | Ribozyme mediated inactivation of the androgen receptor |
| US6784291B2 (en) | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
| US20050159376A1 (en) * | 2002-02-20 | 2005-07-21 | Slrna Therapeutics, Inc. | RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003085110A2 (en) * | 2002-04-05 | 2003-10-16 | Santaris Pharma A/S | Oligomeric compounds for the modulation hif-1alpha expression |
| US7087229B2 (en) * | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| US9045518B2 (en) | 2002-11-18 | 2015-06-02 | Santaris Pharma A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
| US20070141009A1 (en) * | 2003-01-03 | 2007-06-21 | Shaharyar Khan | Sirna mediated post-transriptional gene silencing of genes involved in alopecia |
| JP2006518999A (ja) * | 2003-02-10 | 2006-08-24 | サンタリス・ファルマ・アクティーゼルスカブ | チオレドキシン発現の改変のためのオリゴマー化合物 |
| US20040248840A1 (en) * | 2003-02-10 | 2004-12-09 | Santaris Pharma A/S | Oligomeric compounds for the modulation of ras expression |
| MXPA05011022A (es) * | 2003-04-13 | 2006-04-27 | Enzon Pharmaceuticals Inc | Profarmacos oligonucleotidos polimericos. |
| CA2538729A1 (en) | 2003-09-12 | 2005-03-31 | Avi Biopharma, Inc. | Compound and method for treating androgen-independent prostate cancer |
| US20050164970A1 (en) * | 2003-12-22 | 2005-07-28 | University Of Kansas Medical Center | Method for treating prostate cancer using siRNA duplex for androgen receptor |
| RU2377301C2 (ru) * | 2003-12-23 | 2009-12-27 | Сантарис Фарма А/С | ОЛИГОМЕРНОЕ СОЕДИНЕНИЕ, ПОНИЖАЮЩЕЕ ЭКСПРЕССИЮ ЧЕЛОВЕЧЕСКОГО ГЕНА Bcl-2, КОНЪЮГАТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ ОЛИГОМЕРНОГО СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ РАКА |
| AU2006291836B2 (en) | 2005-09-15 | 2012-02-23 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-Bl00 expression |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| WO2007041497A2 (en) * | 2005-09-30 | 2007-04-12 | Cleveland Biolabs, Inc. | Modulation of androgen receptor |
| CA2682320A1 (en) * | 2006-05-01 | 2007-11-08 | Aarhus Universitet | An animal model and a method for producing an animal model |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| JP2010503707A (ja) | 2006-09-15 | 2010-02-04 | エンゾン ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー |
| EP2076257A4 (en) | 2006-09-15 | 2014-04-16 | Belrose Pharma Inc | POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS |
| EP2090127A2 (en) | 2006-10-30 | 2009-08-19 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| JP5168944B2 (ja) | 2007-02-28 | 2013-03-27 | 三浦工業株式会社 | 羽根車式流量計 |
-
2008
- 2008-11-26 JP JP2010534367A patent/JP5872162B2/ja not_active Expired - Fee Related
- 2008-11-26 US US12/324,033 patent/US7737125B2/en not_active Expired - Fee Related
- 2008-11-26 MX MX2010005703A patent/MX2010005703A/es active IP Right Grant
- 2008-11-26 DK DK08855697.2T patent/DK2225377T3/da active
- 2008-11-26 KR KR1020107012993A patent/KR20100110298A/ko not_active Ceased
- 2008-11-26 BR BRPI0820508A patent/BRPI0820508A2/pt not_active IP Right Cessation
- 2008-11-26 CN CN200880125544.3A patent/CN101932709B/zh not_active Expired - Fee Related
- 2008-11-26 NZ NZ585327A patent/NZ585327A/xx not_active IP Right Cessation
- 2008-11-26 EA EA201070660A patent/EA020026B1/ru not_active IP Right Cessation
- 2008-11-26 UA UAA201007942A patent/UA100253C2/uk unknown
- 2008-11-26 WO PCT/DK2008/000417 patent/WO2009068033A2/en not_active Ceased
- 2008-11-26 AU AU2008329327A patent/AU2008329327B2/en not_active Ceased
- 2008-11-26 TW TW097145706A patent/TW200930382A/zh unknown
- 2008-11-26 CA CA2705714A patent/CA2705714A1/en not_active Abandoned
- 2008-11-26 EP EP08855697.2A patent/EP2225377B1/en active Active
- 2008-11-26 ES ES08855697.2T patent/ES2456990T3/es active Active
-
2010
- 2010-03-18 US US12/726,554 patent/US7989429B2/en not_active Expired - Fee Related
- 2010-05-25 IL IL205944A patent/IL205944A/en not_active IP Right Cessation
-
2011
- 2011-05-31 US US13/149,155 patent/US20110319471A1/en not_active Abandoned
-
2012
- 2012-10-11 IL IL222397A patent/IL222397A/en not_active IP Right Cessation
-
2015
- 2015-10-23 JP JP2015208689A patent/JP2016105703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504362A5 (https=) | ||
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| RU2566724C2 (ru) | Композиции и способы модуляции smn2 сплайсинга у субъекта | |
| JP6622214B2 (ja) | Ｓｏｄ−１発現を調節するための組成物 | |
| CN105517556B (zh) | 前激肽释放酶(pkk)表达的调节 | |
| CA3106312C (en) | CHIMERIC DOUBLE-STRANDED NUCLEIC ACID | |
| JP2018184423A5 (https=) | ||
| JP2010524486A5 (https=) | ||
| JP2011526482A5 (https=) | ||
| TW202307207A (zh) | 用於抑制黃嘌呤脫氫酶(XDH)之表現之RNAi藥劑、其醫藥組合物及使用方法 | |
| JP2012050438A5 (https=) | ||
| JP2009532044A5 (https=) | ||
| JP2021527437A (ja) | Ｓｃｎ９ａ発現を調節するためのオリゴヌクレオチド | |
| JP2012508560A5 (https=) | ||
| JP2009532392A5 (https=) | ||
| JP2016530882A5 (https=) | ||
| PT1910395E (pt) | Composições e métodos para a modulação do''splicing'' de smn2 | |
| JP2005503142A5 (https=) | ||
| JP2009508527A5 (https=) | ||
| JP2012029693A5 (https=) | ||
| EP3790971A1 (en) | Oligonucleotides for modulating myh7 expression | |
| BR112020020220A2 (pt) | Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b | |
| JP2015511821A5 (https=) | ||
| JP2021524277A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2011505798A5 (https=) |